Literature DB >> 22761122

Does perioperative furosemide usage reduce the need for renal replacement therapy in cardiac surgery patients?

Ajay Gandhi1, Mubassher Husain, Kareem Salhiyyah, Shahzad G Raja.   

Abstract

A best evidence topic was constructed according to a structured protocol. The question addressed was 'Does perioperative furosemide usage reduce the need for renal replacement therapy in cardiac surgery patients?' Forty-seven papers were found using the reported search, of which 10 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Current best available evidence to resolve the issue includes a systematic review and nine randomized controlled trials (RCTs). The systematic review of seven RCTs and one observational study has demonstrated that in patients who have undergone cardiac surgery, a more consistent and sustained diuresis is produced by a continuous infusion of furosemide compared with intermittent bolus doses of furosemide. However, there does not appear to be a significant difference in the total urine output or a change in serum electrolyte levels when furosemide is administered as a continuous infusion compared with intermittent bolus doses. Three RCTs recruiting neonatal and paediatric patients after open heart surgery also validated the safety and efficacy of furosemide infusion as well as intermittent bolus doses. Two of the five RCTS in adult cardiac surgery patients showed that furosemide infusion was associated with a reduced need for renal replacement therapy (RRT), while two RCTs failed to show any benefit and one reported an increased incidence of renal impairment. We conclude that continuous furosemide infusion in the perioperative period promotes a gentle and sustained diuresis in cardiac surgery patients. The evidence supporting the benefit of this strategy in terms of reducing the need for RRT is weak. At the same time, current best available evidence, albeit from small RCTs, suggests that the timely introduction of continuous furosemide infusion does not increase the incidence of renal impairment after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761122      PMCID: PMC3445350          DOI: 10.1093/icvts/ivs208

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  11 in total

1.  Evaluating routine diuretics after coronary surgery: a prospective randomized controlled trial.

Authors:  Eric Lim; Ziad A Ali; Robert Attaran; Graham Cooper
Journal:  Ann Thorac Surg       Date:  2002-01       Impact factor: 4.330

2.  Intermittent administration of furosemide versus continuous infusion in the postoperative management of children following open heart surgery.

Authors:  J M Klinge; J Scharf; M Hofbeck; S Gerling; S Bonakdar; H Singer
Journal:  Intensive Care Med       Date:  1997-06       Impact factor: 17.440

3.  Towards evidence-based medicine in cardiothoracic surgery: best BETS.

Authors:  Joel Dunning; Brian Prendergast; Kevin Mackway-Jones
Journal:  Interact Cardiovasc Thorac Surg       Date:  2003-12

4.  Comparison of continuous versus intermittent furosemide administration in postoperative pediatric cardiac patients.

Authors:  N C Singh; N Kissoon; S al Mofada; M Bennett; D J Bohn
Journal:  Crit Care Med       Date:  1992-01       Impact factor: 7.598

5.  Lack of renoprotective effects of dopamine and furosemide during cardiac surgery.

Authors:  Andrea Lassnigg; Eva Donner; Georg Grubhofer; Elisabeth Presterl; Wilfred Druml; Michael Hiesmayr
Journal:  J Am Soc Nephrol       Date:  2000-01       Impact factor: 10.121

6.  Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery.

Authors:  S Sirivella; I Gielchinsky; V Parsonnet
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

Review 7.  Efficacy and safety of a furosemide continuous infusion following cardiac surgery.

Authors:  Brian E Gulbis; Anne P Spencer
Journal:  Ann Pharmacother       Date:  2006-09-05       Impact factor: 3.154

8.  Continuous versus intermittent furosemide infusion in critically ill infants after open heart operations.

Authors:  G B Luciani; S Nichani; A C Chang; W J Wells; C J Newth; V A Starnes
Journal:  Ann Thorac Surg       Date:  1997-10       Impact factor: 4.330

9.  Furosemide infusion prevents the requirement of renal replacement therapy after cardiac surgery.

Authors:  Atike Tekeli Kunt; Serdar Akgün; Nazan Atalan; Nazan Bitir; Sinan Arsan
Journal:  Anadolu Kardiyol Derg       Date:  2009-12

10.  Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.

Authors:  Balakrishnan Mahesh; Boyd Yim; Desiree Robson; Ravi Pillai; Chandana Ratnatunga; David Pigott
Journal:  Eur J Cardiothorac Surg       Date:  2008-03       Impact factor: 4.191

View more
  9 in total

1.  Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.

Authors:  Hiroyuki Nishi; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Satsuki Fukushima; Masashi Kawamura; Daisuke Yoshioka; Tetsuya Saito; Takayoshi Ueno; Toru Kuratani; Yoshiki Sawa
Journal:  Surg Today       Date:  2015-09-28       Impact factor: 2.549

2.  Optimal timing of renal replacement therapy for favourable outcome in patients of acute renal failure following cardiac surgery.

Authors:  Shanshank Tripathi; Shantanu Pande; Pulkit Malhotra; Supaksh Mahindru; Ankit Thukral; Ankush Singh Kotwal; Gauranga Majumdar; Surendra Kumar Agarwal; Amit Gupta
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-09-05

3.  A study of the efficacy of furosemide as a prophylaxis of acute renal failure in coronary artery bypass grafting patients: A clinical trial.

Authors:  Fatemeh Bayat; Zahra Faritous; Nahid Aghdaei; Ali Dabbagh
Journal:  ARYA Atheroscler       Date:  2015-05

4.  Prophylactic furosemide infusion decreasing early major postoperative renal dysfunction in on-pump adult cardiac surgery: a randomized clinical trial.

Authors:  Solmaz Fakhari; Fariba Mirzaei Bavil; Eissa Bilehjani; Sona Abolhasani; Moussa Mirinazhad; Bahman Naghipour
Journal:  Res Rep Urol       Date:  2017-01-19

5.  Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials.

Authors:  Tiziana Bove; Alessandro Belletti; Alessandro Putzu; Simone Pappacena; Giuseppe Denaro; Giovanni Landoni; Sean M Bagshaw; Alberto Zangrillo
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

6.  Risk factors for renal failure and short-term prognosis in patients with spontaneous intracerebral haemorrhage complicated by acute kidney injury.

Authors:  Zhenhuan Zou; Siying Chen; Yinshuang Li; Jiawei Cai; Yulu Fang; Jingzhi Xie; Wenhua Fang; Dezhi Kang; Yanfang Xu
Journal:  BMC Nephrol       Date:  2020-07-29       Impact factor: 2.388

7.  Recruitment of sublingual microcirculation using handheld incident dark field imaging as a routine measurement tool during the postoperative de-escalation phase-a pilot study in post ICU cardiac surgery patients.

Authors:  Zühre Uz; Can Ince; Philippe Guerci; Yasin Ince; Renata P Araujo; Bulent Ergin; Matthias P Hilty; Thomas M van Gulik; Bas A de Mol
Journal:  Perioper Med (Lond)       Date:  2018-08-09

8.  Preoperative use of furosemide may increase the incidence of acute kidney injury after coronary artery bypass grafting: a propensity score-matched study.

Authors:  Hui Zheng; Le Liu; Guoliang Fan; Zhigang Liu; Zhengqing Wang; Baocheng Chang
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-02-06

9.  The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.

Authors:  Tomoko S Kato; Hiroshi Nakamura; Mai Murata; Kishio Kuroda; Hitoshi Suzuki; Yasutaka Yokoyama; Akie Shimada; Satoshi Matsushita; Taira Yamamoto; Atsushi Amano
Journal:  BMC Cardiovasc Disord       Date:  2016-09-13       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.